Sarepta Therapeutics, Inc.
215 First Street
Cambridge, MA -2142
United States
839 articles about Sarepta Therapeutics, Inc.
-
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
9/27/2021
Sarepta Therapeutics, Inc. today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter.
-
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
9/14/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, 2021.
-
Selecta and Cyrus' partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences in September 2021
9/7/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2021
8/31/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in August 2021.
-
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
8/4/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that upon completion of a number of preclinical and safety studies, it had executed an exclusive license agreement for an investigational gene therapy candidate, calpain 3 (CAPN-3), to treat Limb-girdle muscular dystrophy type 2A (LGMD2A), developed by the Abigail Wexner Research Institute at Nationwide Children’s Hospital (Nationwide Children’s).
-
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
8/4/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2021.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 30, 2021
7/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on July 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in July 2021.
-
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
7/28/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2021
6/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021.
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences - June 03, 2021
6/3/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences
-
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
-
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001
5/18/2021
Results from the first 11 participants enrolled in Study 9001-103 ENDEAVOR showed robust transduction, delivering mean vector genome copies of 3.87 per nucleus Treated patients achieved mean micro-dystrophin expression levels of 55.4% of normal as measured by western blot
-
Sarepta Therapeutics announced its gene therapy candidate, SRP-9001, shows "robust expression and consistent safety profile."
-
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
5/17/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 12-week expression and safety results from Study SRP-9001-103 (Study 103), also known as ENDEAVOR.
-
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
-
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
5/5/2021
Net product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year
-
Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences - May 04, 2021
5/4/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences
-
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
5/3/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051